CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs
By
Carie Behounek
Summary
Orforglipron is an FDA-approved non-peptide oral GLP-1 pill being studied as an alternative to injectable weight-loss drugs like Ozempic and Wegovy. A clinical trial at CU Anschutz, led by researcher Dr. Cecilia Low Wang, is investigating the drug's efficacy and safety. Patient Julia Swaney shares her two-year experience in the trial, describing how the medication quieted her "food noise" and led to significant weight loss. The article explores the broader context of GLP-1 drug demand, access barriers due to cost and injectable delivery, and the potential of oral alternatives to expand treatment options for obesity and related conditions.
Source
Twitter / XCU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugsnews.cuanschutz.eduKey quotes
· 3 pulledEvery morning for two years, Julia Swaney has popped a pill, hoping it would quiet the 'food noise' she's struggled with since she was a teen.
The pill she takes has had no effects, other than making her feel full faster and helping her lose 40 pounds.
Demand for GLP-1 medications has surged in recent years, but cost and injectable delivery have limited access for many patients.
You might also wanna read
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·6mo ago
Daily weight loss pill available in UK pharmacies from today
Study Finds GLP-1 Drug Users Show Decreased Physical Activity Levels
A new study presented by doctors at HSHS Saint John's Hospital in Illinois found that people taking GLP-1 drugs like Ozempic and Wegovy sign
gizmodo.com·23d ago
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr
gizmodo.com·1mo ago
Study: Ozempic and Wegovy Reduce Household Food Spending and Change Purchasing Patterns
New research published in the Journal of Marketing Research shows that GLP-1 receptor agonist drugs like Ozempic and Wegovy are significantl
news.cornell.edu·5mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Comments
Sign in to join the conversation.
No comments yet. Be the first.